| Original language | English (US) |
|---|---|
| Pages (from-to) | 797-800 |
| Number of pages | 4 |
| Journal | Expert review of cardiovascular therapy |
| Volume | 9 |
| Issue number | 7 |
| DOIs | |
| State | Published - Jul 2011 |
Bibliographical note
Funding Information:Ali A Sovari is funded by the American Heart Association Midwest Affiliate Postdoctoral Fellowship Award (grant no. AHAA10POST4450037). Samuel C Dudley is funded by the National Institute of Health (grant no. RO1 RO1HL085558, PO1 HL058000). Samuel C Dudley has the following pending patents: Prevention of sudden death by modulation of Src family (application no. 13/032,629); Modulating mitochondrial reactive oxygen species to increase cardiac sodium current and mitigate sudden death (application no. CIP 12/929786); Oxidative stress markers predict atrial fibrillation (application no. 11/882,627). Ali A Sovari and Samuel C Dudley have the pending patent: Mitochondria anti-oxidants for prevention of sudden death by raising connexin43 levels (application no. 61/503,096). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
Keywords
- antiarrhythmic
- arrhythmia
- atrial fibrillation
- oxidative stress
- sudden cardiac death
